[EN] ALKOXY COMPOUNDS FOR DISEASE TREATMENT<br/>[FR] COMPOSÉS D'ALCOXY POUR LE TRAITEMENT DE MALADIES
申请人:ACUCELA INC
公开号:WO2009045479A1
公开(公告)日:2009-04-09
The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY
申请人:MICURX PHARMACEUTICALS, INC.
公开号:US20130165411A1
公开(公告)日:2013-06-27
Provided herein are antimicrobial tricyclic boron compounds of the following formula I:
or pharmaceutically acceptable salts, complexes, or tautomers thereof that are antibacterial agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.
[EN] PROCESS FOR PREPARING BENZOXABOROLES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE BENZOXABOROLES
申请人:GLAXOSMITHKLINE LLC
公开号:WO2011127143A1
公开(公告)日:2011-10-13
The present invention is a process comprising contacting a compound of formula 6: or a pharmaceutically acceptable salt thereof; with a deprotecting reagent to form a compound of formula A: or a pharmaceutically acceptable salt thereof; where R is H or OR1; R1 and each R1' are protecting groups; R1" is H or OH, and n is 0, 1, 2, 3, 4, or 5.
Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
The present invention is a process comprising contacting a compound of formula 6:
or a pharmaceutically acceptable salt thereof;
with a deprotecting reagent to form a compound of formula A:
or a pharmaceutically acceptable salt thereof;
where R is H or OR1; R1 and each R1′ are protecting groups; R1″ is H or OH, and n is 0, 1, 2, 3, 4 , or 5.